VIRUS-INACTIVATING AND RNA/DNA/ANTIGEN-PRESERVING TRANSPORT MEDIUM
DRDP™
- virus inactivation
- stabilizes RNA
- stabilizes DNA
- stabilizes antigen
- direct PCR compatible
(no extraction required)
DRDP™ is a universal virus-inactivating medium intended for the collection and transport of upper respiratory specimens (saliva, nasal swab) for in vitro diagnostic testing on the presence of antigens or genetic material (i.e. viral RNA, human RNA/DNA).
DRDP™ can be used in rapid antigen lateral flow tests, and in molecular methods such as (RT-)qPCR.
DRDP™ is suitable for direct PCR in your specific test system upon validation (i.e. no extraction and/or purification needed).
performance information
- complete inactivation of viruses within 60 minutes
- stabilization of DNA / RNA up to 8 days after collection when stored between 2-25 °C, resistance to repeated freeze/thaw cycles
- antigen preservation for up to 24 hours, compatible with a broad range of rapid antigen lateral flow tests after neutralization of pH
- suitable for direct PCR in your specific test system upon validation (more details in the instructions for use)
Virus inactivation
The validation study comprised the following viruses, all of them were completely inactivated:
| complete inactivation | ||||
|---|---|---|---|---|
| RNA viruses | MERS-CoV | SARS-CoV-2 | bovine RSV virus | H5N1 |
| DNA viruses | monkeypox (mpox) | vaccinia | ||
RNA / DNA stabilization
The validation study demonstrated the following stability for the indicated targets:
| nasal swab | saliva | |||
|---|---|---|---|---|
| assay / storage temperature | 4 °C | 25 °C | 4 °C | 25 °C |
| human DNA (GADPH, RSP18) | 8 days | 8 days | 8 days | 8 days |
| human RNA (CALR, TEMED2) | 8 days | 8 days | 8 days | 8 days |
| viral RNA (SARS-CoV-2 viral particles) | 8 days | 2 days | 8 days | not determined |
Antigen preservation
Experiments have demonstrated that DRDPTM preserves antigens for at least 24 h. To this end, commercially available rapid antigen lateral flow tests were loaded with DRDPTM with or without clinical matrix and with or without SARS-CoV-2 spiking. pH was neutralized as described in the instructions for use leaflet. A clear signal was obtained in test (T) and control (C) strips at time 0 and after 24 h.
| positive | negative | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Newgene (SUNGO Europe BV) | time = 0 | time = 24 h | time = 0 | time = 24 h | |||||
| matrix | replicated | control | test | control | test | control | test | control | test |
| no matrix | 1 | + | + | + | + | + | - | + | - |
| 2 | + | + | + | + | |||||
| 3 | + | + | + | + | |||||
| nasal swab | 1 | + | + | + | + | + | - | + | - |
| 2 | + | + | + | + | |||||
| 3 | + | + | + | + | |||||
| saliva | 1 | + | + | + | + | + | - | + | - |
| 2 | + | + | + | + | |||||
| 3 | + | + | + | + | |||||
Publications
International Journal of Molecular Sciences
Assessment of DNA/RNA Defend Pro: an inactivating sample collection buffer for enhanced stability, extraction-free PCR, and rapid antigen testing of nasopharyngeal swab samples., Claeys et al., 2024
medRxiv
Evaluation of a novel respiratory virus inactivating buffer for parallel RT-qPCR and quick antigen testing., Deprez et al., 2024